We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Doximity (DOCS) Stock Dips While Market Gains: Key Facts
Read MoreHide Full Article
In the latest trading session, Doximity (DOCS - Free Report) closed at $22.25, marking a -1.81% move from the previous day. The stock's change was less than the S&P 500's daily gain of 1.18%. On the other hand, the Dow registered a gain of 0.66%, and the technology-centric Nasdaq increased by 1.96%.
Heading into today, shares of the medical social networking site had lost 7.85% over the past month, lagging the Medical sector's loss of 1.56% and the S&P 500's gain of 3.93%.
Analysts and investors alike will be keeping a close eye on the performance of Doximity in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $0.28, marking a 26.32% fall compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $143.67 million, indicating a 3.89% upward movement from the same quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $1.54 per share and a revenue of $643.12 million, representing changes of +8.45% and +12.75%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for Doximity. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Doximity currently has a Zacks Rank of #4 (Sell).
Looking at valuation, Doximity is presently trading at a Forward P/E ratio of 14.19. This indicates a discount in contrast to its industry's Forward P/E of 19.95.
Investors should also note that DOCS has a PEG ratio of 0.88 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical Info Systems industry currently had an average PEG ratio of 1.16 as of yesterday's close.
The Medical Info Systems industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 93, positioning it in the top 39% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Doximity (DOCS) Stock Dips While Market Gains: Key Facts
In the latest trading session, Doximity (DOCS - Free Report) closed at $22.25, marking a -1.81% move from the previous day. The stock's change was less than the S&P 500's daily gain of 1.18%. On the other hand, the Dow registered a gain of 0.66%, and the technology-centric Nasdaq increased by 1.96%.
Heading into today, shares of the medical social networking site had lost 7.85% over the past month, lagging the Medical sector's loss of 1.56% and the S&P 500's gain of 3.93%.
Analysts and investors alike will be keeping a close eye on the performance of Doximity in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $0.28, marking a 26.32% fall compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $143.67 million, indicating a 3.89% upward movement from the same quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $1.54 per share and a revenue of $643.12 million, representing changes of +8.45% and +12.75%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for Doximity. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Doximity currently has a Zacks Rank of #4 (Sell).
Looking at valuation, Doximity is presently trading at a Forward P/E ratio of 14.19. This indicates a discount in contrast to its industry's Forward P/E of 19.95.
Investors should also note that DOCS has a PEG ratio of 0.88 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical Info Systems industry currently had an average PEG ratio of 1.16 as of yesterday's close.
The Medical Info Systems industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 93, positioning it in the top 39% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.